BMS Exec Discusses Q1 Performance, Growth Brands, Pipeline

Lamberto Andreotti
Executive Vice President
&
Chief Operating Officer

Deutsche Bank Healthcare Conference
May 7, 2008

This presentation is intended solely for an investment community/industry audience-not for promotional use
community/industry audience-

May 7, 2008

During this meeting, we will make statements about the Company’s future
plans and prospects, including statements about our financial position,
business strategy, research pipeline concerning product development and
product potential, that constitute forward-looking statements for purposes
of the safe harbor provisions under the Private Securities Litigation Reform
Act of 1995.
Actual results may differ materially from those indicated by these forward-
looking statements as a result of various important factors, including those
discussed in the company’s most recent annual report on Form 10-K,
periodic reports on Form 10-Q and current reports on Form 8-K. These
documents are available from the SEC, the Bristol-Myers Squibb website
or from Bristol-Myers Squibb Investor Relations.
In addition, any forward-looking statements represent our estimates only as
of today and should not be relied upon as representing our estimates as of
any subsequent date. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change.

community/industry audience-

Next Generation BioPharma

Best of Pharma
Best of Biotech

Next Generation
BioPharma

Selectively
Innovative Continuous
Integrated
Portfolio Improvement
Business Model

Agile, Entrepreneurial and Accountable Culture

community/industry audience- 3

Q1 2008 Performance

Strong underlying sales growth +9%
Gross and operating margin improvement
Non-GAAP EPS of $0.42 vs. $0.36 Q1 2007
Decision to retain Mead Johnson within
business portfolio
Recent announcement to sell ConvaTec
Confirmed 3 year non-GAAP guidance

All GAAP to non-GAAP reconciliations are available on our website.

Q1 2008 Sales: Growth Brands
$1,400
$1,308
+39%
$1,200

$1,000

$800
$M
$600
$454
$400 +24% $297
$305 $273
$187
+13% +13% +21%
$200
+17%
$0
Plavix Abilify Avapro Reyataz Sustiva Erbitux


Q1 2008 Sales: New Products
$120
$108
+140%
$100
$87
$80 +112%
$66
$M $60 +314%

$40
$25
$20

$0
Baraclude Orencia Sprycel Ixempra


Plavix Indications
Potential Patient
Proven Efficacy
and Safety Population ~49 million
Indicated for use in broad
patient population Other CV
~28 million
Efficacy and safety of ACS / Stent
Plavix well understood ~1.5 million
ACS
PAD Stroke
Increased hospital
~3 million
~8 million ~10 million
resources focused
on risk benefit ACS / Non-Stent
~1.5 million
Growth opportunities
within ACS as well as
stroke and PAD


Abilify – Broad Clinical Profile and
Specialty Execution

Q1 global sales up 24%

Broadest set of indications for any atypical

US approval in major depressive disorder

EU approval for bipolar mania

Succesful DTC campaign


Orencia – Goal to Become
the IV Biologic of Choice

Q1 sales $87 million +112%
Focus on efficacy and durability of response
Recent label change broadening indication
regardless of prior treatment
Promotional programs focused on
compliance and persistence
DTC campaign focused on defining
inadequate response


Our Productivity Approach
Management Council
Productivity Transformation Team

Supply Chain R&D G&A
Commercial
Operations
$400 MM $200 MM $550 MM $350 MM

$1.5 Billion
Cost Savings + Cost Avoidance


Supply Chain Redesigned to Support
BioPharma Model
Strategic Filters
Current 2011
27 Plants >50% Reduction

Future Geographic Product
Portfolio Footprint Rationalization

Network segmented and specialized
In-house Biologics capability
Aggressive outsourcing of mature products

Generating $400 Million in Productivity

Customer Model Restructured
to Support BioPharma
12,000
Primary Care
10,000
Specialty
8,000 Field-Based Medical
FTEs
Total Field Force
6,000

4,000

2,000

0
2005 2006 2007 2008
Specialty Model synergizes Sales Force and Field-Based
Medical experts
Partnering on Primary Care maximizes capacity and
capability while minimizing fixed overhead
Increasing productivity

Key 2008 Events
ASCO
– Erbitux FLEX data
– Sprycel phase II prostate data
– Ipilimumab data
ADA
– Saxagliptin phase III data
– Dapaglifozin phase IIb data
EASD
– Saxagliptin phase III data
ASH
– Apixiban phase III data

Next Generation BioPharma

Best of Pharma
Best of Biotech

Next Generation
BioPharma

Selectively
Innovative Continuous
Integrated
Portfolio Improvement
Business Model

Agile, Entrepreneurial and Accountable Culture


BMS Exec Discusses Q1 Performance, Growth Brands, Pipeline

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Ähnlich wie BMS Exec Discusses Q1 Performance, Growth Brands, Pipeline

Ähnlich wie BMS Exec Discusses Q1 Performance, Growth Brands, Pipeline (20)

Mehr von finance13

Mehr von finance13 (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

BMS Exec Discusses Q1 Performance, Growth Brands, Pipeline